News

Vantia Therapeutics appoints new CEO

9 June 2010

Vantia Therapeutics today announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO). more»

VA111913 structure revealed

26 March 2010

Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913, at the ACS National Meeting. more»

Vantia Therapeutics Pipeline - Business Development

Vantia Therapeutics' strategy is to develop its proprietary drug candidates to Phase II proof-of-concept and then commercialise through partnerships.

For more information on the product opportunities in development, please contact: